EHA 2026 Conference
- Home
- EHA Conference 2026
Novartis Expands the Potential Role of KYMRIAH into Frontline High-Risk MRD-Positive Pediatric and Young Adult B-ALL
This Phase II CASSIOPEIA/COG AALL1721 study demonstrated that tisagenlecleucel (KYMRIAH) induced durable remissions in pediatric and young adult patients with high-risk B-cell ALL who remained MRD-positive after frontline consolidation therapy. The study met its objective of evaluating CAR-T therapy in a population historically associated with poor long-term outcomes. High MRD clearance rates were observed after infusion, while long-term survival outcomes remained encouraging with a favorable safety profile and low rates of severe CRS and ICANS.
Our Recent Articles
Types / Technology
Indications
Title
Novartis Expands the Potential Role of KYMRIAH into Frontline High-Risk MRD-Positive Pediatric and Young Adult B-ALL
Summary
This Phase II CASSIOPEIA/COG AALL1721 study demonstrated that tisagenlecleucel (KYMRIAH) induced durable remissions in pediatric and young adult patients with high-risk B-cell ALL who remained MRD-positive after frontline consolidation therapy. The study met its objective of evaluating CAR-T therapy in a population historically associated with poor long-term outcomes. High MRD clearance rates were observed after infusion, while long-term survival outcomes remained encouraging with a favorable safety profile and low rates of severe CRS and ICANS.
Title
Dara-KRd Produces Deep Responses and Durable MRD Negativity in High-Risk Smoldering Multiple Myeloma: Long-Term ASCENT Update
Summary
This trial evaluated a fixed-duration intensive quadruplet regimen comprising daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in patients with high-risk smoldering multiple myeloma. With more than four years of follow-up, the study demonstrated high response rates, deep MRD negativity, and durable progression-free survival, supporting the concept that aggressive intervention at the precursor stage may substantially alter disease trajectory.
Title
Genmab and AbbVie Strengthen Epcoritamab’s Position in Follicular Lymphoma with Broad Subgroup Benefits from EPCORE FL-1
Summary
Subgroup analyses from the Phase III EPCORE FL-1 trial demonstrated that fixed-duration epcoritamab combined with lenalidomide and rituximab delivered consistent efficacy benefits across clinically relevant patient populations with R/R FL. Improvements in overall response rates (ORR), complete response (CR) rates, and progression-free survival (PFS) were observed irrespective of baseline risk features, disease fitness scores, POD24 status, or lenalidomide dose intensity, while maintaining a manageable safety profile.
Title
VT-EBV-N Emerges as a Potential Post-Remission Standard in EBV-Positive Extranodal NK/T-Cell Lymphoma
Summary
The randomized Phase II trial demonstrated that VT-EBV-N, an autologous EBV-specific cytotoxic T-cell therapy, significantly improved 2-year disease-free survival (DFS) compared with control in patients with EBV-positive extranodal NK/T-cell lymphoma who had achieved complete remission (CR) after prior therapy. The treatment was well tolerated and represents one of the first randomized studies to establish a post-remission strategy in this rare and aggressive lymphoma.
Title
Overcoming CAR-T Resistance: OL-101 demonstrates deep and durable responses in Myeloma
Summary
In the first-in-human Phase I/II study, OL-101 achieved a 100% overall response rate with deep and rapid responses, including a high rate of very good partial responses or better and stringent complete responses, alongside universal minimal residual disease negativity and robust CAR-T cell expansion kinetics. Importantly, clinically meaningful activity was retained in traditionally refractory subgroups, reinforcing the potential of dual-antigen targeting to overcome antigen escape and prior immunotherapy resistance. The safety profile was consistent with class effects of CAR-T therapy, dominated by cytokine release syndrome and reversible hematologic toxicities, without new safety signals, supporting continued clinical development in this high-risk population.
Title
First-Line Sonrotoclax and Zanubrutinib Induce High uMRD Rates Across CLL/SLL Risk Groups
Summary
Sonrotoclax (BEQALZI), a next-generation, highly selective B-cell lymphoma 2 (BCL2) inhibitor, demonstrated exceptional efficacy in combination with zanubrutinib in frontline CLL/SLL, achieving a 100% overall response rate, deep MRD-negative remissions, and durable disease control across high-risk subgroups, including TP53-aberrant and unmutated IGHV disease. The regimen was well tolerated, with no tumor lysis syndrome, no treatment-related deaths, and minimal treatment discontinuations due to adverse events, reinforcing sonrotoclax’s potential as a best-in-class BCL2 inhibitor and a promising fixed-duration treatment strategy.
Case Studies
Conference Coverage In Various Oncology Conferences
Learn how a big pharma company leveraged conference coverage solutions to comprehensively covert, ASCO, AACR, and ESMO by meticulous conference planning
Conference Coverage For CI Insights On Liquid Biopsy
Find out how a top liquid biopsy company used ESMO congress coverage to track competitor tests and data readouts.
NSCLC Epidemiology Forecasting Strategy
Learn how DelveInsight assisted a client with NSCLC epidemiology forecasting segmented by biomarker types.
Market Assessment
Find out how a global pharma company evaluated the market potential of assets gained through the acquisition
Newsletter and Whitepapers
Major Hike Anticipated in the AML Market Due to the Presence of a Robust Pipeline
Currently, the AML sphere constitutes a robust pipeline with more than 250+ drugs under different phases of development. Even with the presence of so many therapeutic drugs, there is still a need for targeted palliative care interventions and therapies with lower toxicity and better efficacy. Learn about the recent happenings, ongoing research & development, and significant pharmaceutical companies involved in the AML treatment market.
Latest Reports
-market.png&w=3840&q=75)
-market.png&w=3840&q=75)
Get Expert Consultation Now!
Our extensive history and deep knowledge in the field of hematology make us an ideal ally for addressing your urgent business challenges.
Leveraging our comprehensive understanding of the hematology pipeline, nuanced grasp of market dynamics, and keen insight into marketing intricacies, we can assist you in devising a highly effective strategy for future success.
Reach out to us to explore potential collaboration opportunities and learn more about the valuable solutions we can provide.
Delivering value through our expansive service offerings
Considering the ever-changing nature of the hematology therapy field, it's crucial to establish a competitive advantage for your business as soon as possible. Our range of consulting services and market research resources positions us well to guide you through obstacles while maximizing your strengths and opportunities.
We provide valuable insights to enhance your competitive edge and develop successful growth strategies. Join us on a journey to uncover opportunities and avoid pitfalls, as we simplify the process of optimizing your return on investment through our expert guidance.
Involve us to help you collect insights on which asset could hold the most potential in the future.
Our 11-year forecast provides foresight for effective strategy-building for successful market entry
Our research expertise delivers real-time information that elevates your business decisions
We assist in navigating the tricky drug development terrain by providing intelligence assessments